Introduction
The process of nutritional and functional decline in the patient with cancer is so common that it is often accepted as part of cancer treatment and the disease itself. The clear link between weight loss, poor performance status, poor response to treatment and poor prognosis is probably due to the preferential loss of skeletal muscle. It has been suggested that the loss of adipose tissue accounts for the majority of the weight loss, but the loss of muscle for most of the morbidity and mortality [1, 2] .
However, the degree of weight loss that is prognostic is not well defined and performance status is recognized to be subjective and therefore their reliability has been questioned [1, 2] . Moreover, they do not provide objective therapeutic targets. There is now good consistent evidence that the presence of a systemic inflammatory response is associated with increased weight loss, an elevated resting energy expenditure, loss of lean tissue and functional decline. Furthermore, the use of anti-inflammatory agents is associated with moderation of weight loss and the maintenance of performance status and quality of life in patients with advanced cancer [3 ,4 ] .
Measurement of the systemic inflammatory response
The basis of the systemic response in cancer patients is not clear; it may result from a nonspecific response secondary to tumour hypoxia/necrosis or local tissue damage. Nevertheless, host responses to such systemic inflammation are myriad. These include alterations in neuroendocrine metabolism including the endocrine hormones, haematopoietic changes, including the interleukins, interferons and the haematopoietic growth factors and acute phase proteins [5] . The liver, in particular hepatocytes are central to the elaboration of the systemic inflammatory response as they are stimulated to synthesize and release into the systemic circulation a variety of acute phase proteins, such as C-reactive protein (CRP), which initiate or sustain the systemic inflammatory response. CRP, due to its sensitivity, specificity and
Purpose of review
There is now good evidence in humans that a chronic systemic inflammatory response results in the cardinal features of cancer cachexia, principally the progressive loss of weight (in particular lean tissue). This review examines the role of recent simple objective systemic inflammation-based scores in predicting reduction of nutritional status and survival.
Recent findings
The most common measure of the systemic inflammatory response in cancer patients has been an elevated C-reactive protein concentration. This has now been included in recent definitions of cancer cachexia. There are also recent systemic inflammationbased scores, the Glasgow Prognostic Score, Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio that have been shown to have prognostic value in cancer patients. These scores, in particular the Glasgow Prognostic Score, enable identification of patients who are, or likely, to develop cachexia, have a poor response to treatment and who are likely to have poor survival. Summary A chronic systemic inflammatory response is clearly implicated in the progressive nutritional and functional decline in the cancer patients and their subsequent poor outcome. Systemic inflammation-based prognostic scores not only identify patients at risk but also provide well defined therapeutic targets for future clinical trials targeting nutritional decline. reproducibility of analysis in hospital laboratories, is most commonly used to assess the magnitude (whether acute or chronic) of the systemic inflammatory response. Recently, Marsik et al. [6 ] reported the relationship between CRP and all-cause mortality in approximately 270 000 patients admitted to hospital. With increasing CRP concentrations from normal (<5 mg/l) to highly elevated (>80 mg/l), there was a 3.3-fold increase in the risk of all-cause mortality. The relation of CRP to cancer death was stronger than to vascular death and there was a 22.8-fold increase in cancer mortality in the patients with highly elevated CRP concentrations (>80 mg/l). Indeed, the magnitude of the increase in CRP concentrations has been shown to be associated with poorer survival in cancer patients, particularly in patients with advanced disease, independent of tumour stage [3 ] . There has also been some work in primary operable cancer that has shown that the systemic inflammatory response, as evidenced by an elevated CRP concentration, has prognostic value in gastrooesophageal [7] , urinary bladder [8] , pancreas [9] , renal [10] and nonsmall cell lung [11] cancers, independent of tumour stage. Also, a number of studies carried out in primary operable colorectal cancer have highlighted the independent prognostic value of an elevated CRP concentration [3 ] .
It is of interest that in patients with cancer as CRP increases, albumin falls and this relationship is similar across different tumour types [3 ] and also that albumin concentrations reflect both systemic inflammation and the amount of lean tissue [3 ] . Therefore, the prognostic value of the combination of an elevated CRP concentration (>10 mg/l) and hypoalbuminaemia (<35 g/l) was examined [12] in 161 patients with inoperable nonsmall cell lung cancer. On multivariate survival analysis, this combination (hazard ratio 1.70, 95% CI 1.23-2. 35 , P < 0.001) compared favourably with the clinical standard combination of stage and performance status [hazard ratio 1.48, 95% confidence interval (CI) 1.12-1.95,
This work resulted in the combination of CRP and albumin into a prognostic score (0, 1, 2). This score, now termed the Glasgow Prognostic Score (GPS), was defined as follows: patients with both an elevated CRP (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one of these biochemical abnormalities was present were allocated a score of 1. Patients in whom neither of these abnormalities was present were allocated a score of 0. However, the score of 1 was most commonly due to an elevated CRP (33 out of 35 patients) emphasizing the inflammatory basis of the GPS [12] . This inflammation-based prognostic score (Table 1) has much to commend it, as it has value independent of tumour stage, is simple to measure, routinely available and well standardized worldwide.
The relationship between inflammation-based scores, nutritional status and survival in patients with cancer
The prognostic value of the GPS has been evaluated further in a variety of cancers, including nonsmall cell lung cancer, breast cancer, gastrooesophageal cancer, pancreatic cancer, renal cancer and colorectal cancer ( [13-18,19 ,20 ,21-24,25 ,26] , Table 2 ). These studies demonstrated that the prognostic value of the GPS was independent of tumour stage and conventional scoring systems, superior to performance status and independent of treatment modalities. Moreover, consistent with the cachexia derivation of the systemic inflammation-based GPS [3 ], it was directly associated with elevated cytokine and adipokine concentrations [22, 24] , biochemical disturbance [21] , the loss of weight and lean tissue and loss of performance status [21, 22, 24] .
More recently, the Neutrophil Lymphocyte Ratio (NLR) has been shown to have independent prognostic value in a variety of cancers, including lung cancer, gastric cancer, pancreatic cancer, colorectal cancer, colorectal liver metastases, cholangiocarcinoma and ovarian cancer ( [27,28 ,29 ,30,31 ,32-34] , Table 3 ). Also, the Platelet Lymphocyte Ratio (PLR) has recently been shown to have independent prognostic value in patients undergoing potentially curative resection for pancreatic cancer ( [35] , Table 3 ). These studies demonstrated that the prognostic value of the NLR or the PLR was independent of tumour stage and conventional scoring systems and independent of treatment modalities.
Recently, Leitch et al. [20 ] compared the prognostic value of the GPS and components of the differential white cell count, including the NLR, in patients with either primary operable colorectal cancer (n ¼ 149) or synchronous unresectable liver metastases (n ¼ 84). The GPS was a superior predictor of cancer-specific survival compared with white cell components of the systemic inflammatory response, including the NLR.
Recent reviews on the cause of cancer cachexia have recognized the importance of systemic inflammation and have proposed a measure of systemic inflammation (elevated CRP) in their definitions of cancer cachexia [1,2]. However, such definitions also include highly variable clinical measures such as weight loss, fat free mass and Table 1 An inflammation-based prognostic score, the Glasgow Prognostic Score
Biochemical characteristics Score C-reactive protein 10 mg/l and albumin 35 g/l 0 C-reactive protein 10 mg/l and albumin <35 g/l 0 C-reactive protein >10 mg/l 1 C-reactive protein >10 mg/l and albumin <35 g/l 2 Adapted with permission [3 ].
food intake. In contrast, the GPS is a simple objective measure that reflects cachexia and reliably predicts outcome in cancer patients. Therefore, the GPS may be more suitable measure for the clinical definition of cancer cachexia.
Conclusion
Therefore, it can be concluded that markers of the systemic inflammatory response, in particular the GPS is a reliable tumour stage independent prognostic factor in patients with cancer. Moreover, that a measure of the systemic inflammatory response (GPS) be included, in addition or in preference to the current definitions of cachexia [1,2], with tumour staging as part of the routine assessment of all cancer patients. As a consequence, this will highlight the need not only to treat the tumour but also the systemic inflammatory response.
Further work is required to establish the value of measures of the systemic inflammatory response as stratification factors and selection criteria in randomized trials and as therapeutic targets in patients with cancer.
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